Oil reserves, Indian pharma & more... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Oil reserves, Indian pharma & more...

Feb 19, 2008

  • With the signs of a recession looming large over the US economy, the Federal Reserve and the policymakers are taking all steps necessary to prevent the American consumer from feeling the pinch of an economic slowdown. While the Fed has resorted to interest rate cuts to boost spending, the government has unveiled a package of tax rebates and temporary investment incentives worth US$ 152 bn or just over 1% of its GDP. But given the rising food and energy prices, the likelihood of stagflation seems to be more prominent.

    Juxtapose this against the economic environment in emerging economies, which are shying away from loose monetary policies largely due to inflationary concerns given the firm oil and food prices. Hence, the central banks in these countries and more notably in India, in a bid to contain inflation, are refraining from undertaking interest rate cuts. And very rightly so! This is despite the widening interest rate differential, which is likely to propel further foreign inflows.


  • Crude oil prices continue to hover on a higher terrain and the world's growing demand for the fuel has not helped matters. This means that oil-production will have to be stepped up a notch to bridge the demand supply gap. However, it is not as easy as it seems. While geopolitical issues, war and natural disasters tend to disrupt the supply of oil, many oil experts conclude that the world's oil reserves are depleting. Others claim that while oil is indeed finite, even now there is plenty of oil available. Only, it needs to be brought to the consumers. And therein lies the problem. New technologies would have to be employed to extract oil and convert it into a more usable form - a daunting task indeed. Also, much of what remains of oil lies in remote places making extraction of the same that much more difficult. As per reports published on CNN Money, a US government survey has said that the world has 3 trillion barrels of oil left as compared to the 1 trillion used so far in history.


  • One of the various reasons, which will contribute to the growth of the Indian pharma industry are the rising incomes that will increase the affordability of drugs. At present, India's per capita health expenditure in absolute terms is considerably lower in comparison to countries such as China, Brazil, Malaysia, Russia, the UK and the US. Around 80% of the healthcare payments are borne by the individual in India, as against the developed markets, where only 10% to 30% are borne by individuals. Therefore, besides intense competition, this fact also explains why India is a low-price, high-volume market. Unless a new drug provides a significant therapeutic use, the willingness to purchase a relatively high-priced drug is absent. Thus, for patented drugs to do well, there will have to be increased penetration of health insurance in the country and a significantly better therapeutic use of the patented product to justify the high premium for the same. In the long-term, healthcare expenditure is expected to increase in line with the growth in per-capita income.

    Another thing to be noted is that medical facilities are very outdated and unaffordable for a large-section of the Indian society (70% of the population lives in rural areas). So, by increasing penetration i.e., making adequate medical facilities available, volumes are expected to grow. Besides this, life-style related diseases would increase in line with urbanisation leading to a demand for chronic therapy-related drugs. Given the fact that the cost of medical care for chronic diseases such as diabetes and cardiovascular is higher than acute diseases such as fever, cough and cold, in value terms, Indian healthcare market will grow. This also explains the reason why most of the domestic companies are increasing the focus on lifestyle drugs.


Equitymaster requests your view! Post a comment on "Oil reserves, Indian pharma & more...". Click here!

  

More Views on News

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

Sundaram Bluechip Fund: Will Hold the Stable Horses (Outside View)

Sep 18, 2020

PersonalFn briefly outlines the newly launched NFO note HSBC Corporate Bond Fund.

Wait! Don't Chase Smallcaps Now (Profit Hunter)

Sep 18, 2020

Let the markets take a breather before you jump in.

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

A Contrarian View on Whether You Should Load Up on Small Caps podcast (Views On News)

Sep 17, 2020

Rahul Shah discusses whether the SEBI circular is the perfect time to start investing in good quality small caps

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


Sep 18, 2020 (Close)

MARKET STATS